CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Oculis Holding AG (OCS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Oculis Holding AG (OCS)

Pharmaceutical Preparations · market cap $575M · as of 2026-11-10

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-15 (est.)
Phase 3
Pipeline
7
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Oculis Holding AG (OCS) is a 60-employee ophthalmology-focused company with a ~$575M market cap (~$7.59/share) and $81.3M in cash. Its lead asset is OCS-01, a dexamethasone ophthalmic suspension in Phase 3 for Diabetic Macular Edema (DME). Its pipeline also includes Phase 3 programs in Dry Eye Disease (licaminlimab), Optic Neuritis (privosegtor) and Inflammation/Eye Pain (OCS-01). The only near-term event on our calendar is an estimated December 15, 2026 Phase 3 readout for licaminlimab in Dry Eye Disease, which we rate 9/10 importance. That readout concerns the dry eye program, not the DME lead asset.
The catalyst path
  • 2026-12-15 (est.)Phase 3 · licaminlimabimp 9/10
Pipeline
AssetPhaseIndication
OCS-01Phase 3Inflammation Eye Pain
OCS-05 +SoC (corticosteroid) IV administrationPhase 2Optic Neuritis
Dexamethasone ophthalmic suspension (OCS-01)Phase 3Diabetic Macular Edema
Dexamethasone nanoparticles eye dropsPhase 2Diabetic Macular Edema
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension mg/mLPhase 2Inflammation Corneal
licaminlimabPhase 3Dry Eye Disease
PrivosegtorPhase 3Optic Neuritis
Price & technical context
3-month
-40.9%
6-month
-72.2%
12-month
-59.6%
52-wk range
$6.83–$32.65
vs 50-day MA
-10.0%
vs 200-day MA
-56.1%
Realized vol
74.3%
Max drawdown
-79.1%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for OCS (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.